Nursing Management of Toxicity, Adherence, and Long-Term Care Across First-Line Regimens in EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Panelists discuss the baseline workup nurses and advanced practice providers should complete before the first dose of first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss how patient education should be timed and reinforced across first-line regimens for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss prophylactic versus reactive dermatologic management across first-line regimens for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss how caregivers and families should be built into the education plan at the start of first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss how nurse-driven telephone triage works for patients receiving first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss how grading drives treatment decisions across first-line regimens for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss gastrointestinal management for patients receiving first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss a case-based scenario involving a woman in her late fifties with newly diagnosed epidermal growth factor receptor (EGFR) exon deletion metastatic lung adenocarcinoma, high disease burden, good performance status, and adequate organ function, whose team is intensifying beyond single-agent osimertinib.

Panelists discuss preparing the same patient for amivantamab plus lazertinib as an alternative to chemotherapy-containing first-line therapy in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).

Panelists discuss a case-based scenario involving a man in his seventies with an excellent, durable response to single-agent osimertinib for more than two years, managed in a community clinic, who has chronic low-grade dermatologic toxicity and fatigue, quietly skips doses when his rash flares, and says he is tired of taking pills.

Panelists discuss overlapping toxicities and long-term needs in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), beginning with osimertinib consolidation after chemoradiation, where cough, dyspnea, fatigue, and esophagitis may predate targeted therapy.